Last reviewed · How we verify
Taurolidine heparin — Competitive Intelligence Brief
marketed
Antimicrobial/anticoagulant combination
Infectious Disease / Vascular Access Management
Small molecule
Live · refreshed every 30 min
Target snapshot
Taurolidine heparin (Taurolidine heparin) — Ain Shams University. Taurolidine heparin is a combination antimicrobial and anticoagulant agent that prevents bacterial biofilm formation and thrombosis in vascular access devices.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Taurolidine heparin TARGET | Taurolidine heparin | Ain Shams University | marketed | Antimicrobial/anticoagulant combination |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Antimicrobial/anticoagulant combination class)
- Ain Shams University · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Taurolidine heparin CI watch — RSS
- Taurolidine heparin CI watch — Atom
- Taurolidine heparin CI watch — JSON
- Taurolidine heparin alone — RSS
- Whole Antimicrobial/anticoagulant combination class — RSS
Cite this brief
Drug Landscape (2026). Taurolidine heparin — Competitive Intelligence Brief. https://druglandscape.com/ci/taurolidine-heparin. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab